TWST
Twist Bioscience Corporation
September 24, 2026 · intraday
- Rarity
- 1.83
- Peak move
- +16.50%
- Float cap
- $9.2B
Twist Bioscience Corporation provides synthetic DNA products and services built on its silicon-based DNA synthesis platform. It sells synthetic genes, next-generation sequencing tools, sample preparation, and drug discovery and development products and services to a global customer base across healthcare, chemicals/materials, food/agriculture, and academic research.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
10 events · 4 from SEC or newswire · 0 timed with the move- Key event
insider_saleTwist Bioscience officer and director Emily M. Leproust filed notice to sell 5,203 common shares worth about $922,906 at an average price of $177.38 under a 10b5-1 plan.
SEC144 0001959173-26-007111 - Key event
notable_investor_commentLeerink Partners said Anthropic is funding laboratory testing of 5,000 protein designs using Twist Bioscience's synthetic DNA and called Twist the single most important beneficiary of Anthropic's push into biology.
insider_saleTwist Bioscience SVP, Chief Legal Officer and Corporate Secretary Dennis Cho sold 348 shares on September 21, 2026 at $165.49 for about $57,591 to cover tax withholding on vesting RSUs, leaving him 73,303 shares.
insider_saleTwist Bioscience SVP of Human Resources Paula Green sold 294 shares on September 21, 2026 at $165.49 for about $48,654, leaving her 116,720 shares directly held.
SEC4 0001214659-26-011916Webebs.publicnow.cominsider_saleTwist Bioscience CEO Emily M. Leproust sold 1,687 shares on September 21, 2026 at $165.49 for about $279,183.
SEC4 0001214659-26-011914- Key event
short_reportShort seller Scorpion Capital questioned Twist Bioscience's AI drug-discovery partnership claims, saying Anthropic's blog calls Twist an independent contract research organization rather than a technology partner.
insider_saleTwist Bioscience CEO Emily M. Leproust sold 322,146 common shares at $151.46-$163.39 for about $56.3 million on September 17, 2026 and exercised options at $8.82-$26.66 for 208,708 shares under a Rule 10b5-1 plan adopted June 15, 2026, retaining 620,589 shares.
analyst_ratingLeerink Partners raised its Twist Bioscience price target to $160.00 from $120.00 while reiterating an Outperform rating.
major_contractTwist Bioscience announced an agreement with Eli Lilly's TuneLab AI drug discovery platform to provide antibody characterization data services, including for the AbLab model, with financial terms not disclosed.
class_action_filedClaims administrator Simpluris set a November 17, 2026 proof-of-claim deadline and November 18, 2026 final approval hearing for the $17,050,000 settlement in Peters v. Twist Bioscience Corp. over alleged misstatements about R&D costs, production costs and gross margins.